When you start a GLP-1 treatment, the whole body responds. The skin is no exception. Many people notice changes in the first few weeks — drier skin, itching, or flare-ups of dermatitis they never had before. This is not in your head. It is a real biological response.
Skin changes are common during GLP-1 treatment. Many people notice dryness, itching, or dermatitis flare-ups in the first weeks. Here is what is normal and what needs medical attention.
Why the skin changes
GLP-1 agonists act on the glucagon-like peptide-1 receptor, which is present in multiple tissues including the skin. The main mechanism involves reducing systemic inflammation and improving insulin sensitivity. When insulin sensitivity improves, excess sebum production decreases in people who were prone to oily skin. For those who already had baseline dry skin, the effect can be the opposite: dryness gets worse.
Another factor is the speed of weight loss. When you lose weight quickly, the skin needs to adapt. In areas like the abdomen, arms, and thighs, it is common to develop looseness or stretch marks. That is not dermatitis, but it is a real discomfort.
Dehydration also plays against you. Many people eat less and drink less water during treatment. The skin is the last place in the body to receive available water. The result is flaking, itching, and increased sensitivity to products that previously caused no reaction.
Track your labs and see how your protocol moves your biomarkers.
Track it in the appThe most common complaints
Atopic dermatitis or eczema: appears or worsens in people who already had a predisposition. Red plaques show up, especially in the folds of the elbows, behind the knees, and on the neck. Itching is the most bothersome symptom.
Dry skin (xerosis): fine flaking, a tight feeling, mainly on the face and legs. Many people abandon their usual moisturizer because it seems to stop working.
Induced acne: paradoxically, people with oily skin may notice improvement. But people with combination to dry skin can develop lesions in unusual areas, such as the trunk.
Urticaria and local reactions: in people who inject the peptide, redness and itching may appear at the injection site. This is different from systemic allergy and usually does not prevent treatment.
